Imatinib Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
COGT | C | Cogent Biosciences, Inc. | -0.46 | |
AVTE | D | Aerovate Therapeutics, Inc. | -0.96 | |
IKT | F | Inhibikase Therapeutics, Inc. | -6.15 |
Related Industries: Biotechnology
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
BBC | D | Virtus LifeSci Biotech Clinical Trials ETF | 1.03 | |
PTH | C | Invesco DWA Healthcare Momentum ETF | 0.91 | |
SBIO | C | ALPS Medical Breakthroughs ETF | 0.69 | |
IWC | C | iShares Microcap ETF | 0.27 | |
XBI | D | SPDR S&P Biotech ETF | 0.18 |
Compare ETFs
Date | Stock | Title |
---|---|---|
Sep 30 | COGT | Cogent Biosciences: Need To Wait For More Data For Adequate Differentiation |
- Imatinib
Imatinib, sold under the brand name Gleevec among others, is an oral chemotherapy medication used to treat cancer. Specifically, it is used for chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+), certain types of gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome. It is taken by mouth.Common side effects include vomiting, diarrhea, muscle pain, headache, and rash. Severe side effects may include fluid retention, gastrointestinal bleeding, bone marrow suppression, liver problems, and heart failure. Use during pregnancy may result in harm to the fetus. Imatinib works by stopping the Bcr-Abl tyrosine-kinase. This can slow growth or result in programmed cell death of certain types of cancer cells.Imatinib was approved for medical use in the United States in 2001. It is on the World Health Organization's List of Essential Medicines. A generic version became available in the UK as of 2017.
Popular Now
Recent Comments
- LillyMilly1 on LILM
- LillyMilly1 on LILM
- TraderMike on RYDE what a RIDE!!! Holy Crap!
- Crunching_The_Market on RYDE what a RIDE!!! Holy Crap!
- LillyMilly1 on LILM
From the Blog
Featured Articles